Black Diamond Therapeutics (BDTX) Price & Analysis

Compare

1,599 Followers

BDTX Stock Chart & Stats

$2.79

-$0.07(-3.30%)

At close: Jan 08 4:00 PM EST

$2.79

-$0.07(-3.30%)

Day’s Range― - ―

52-Week Range$1.20 - $4.94

Previous CloseN/A

Volume170.82K

Average Volume (3M)1.01M

Market Cap

$158.96M

Enterprise Value$200.93M

Total Cash (Recent Filing)$135.50M

Total Debt (Recent Filing)$16.04M

Price to Earnings (P/E)7.4

Beta2.08

Next Earnings

Mar 18, 2026

EPS Estimate

-0.18

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.15

Shares Outstanding56,974,915

10 Day Avg. Volume871,879

30 Day Avg. Volume1,007,056

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)1.41

Price to Sales (P/S)0.00

P/FCF Ratio-1.89

Enterprise Value/Market Cap1.26

Enterprise Value/Revenue2.87

Enterprise Value/Gross Profit2.87

Enterprise Value/Ebitda11.46

Forecast

1Y Price Target

$9.00

Price Target Upside222.58% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-0.63

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

CNS ActivityHigh brain penetration produced strong responses in patients with brain metastases, positioning the therapy as a potential leader among TKIs for managing central nervous system disease.

EfficacyPhase II results showed a 60% objective response rate in front-line non-classical EGFR-mutant lung cancer across a wide range of mutations, indicating broad clinical activity that could support regulatory interest.

Financial RunwayBetter-than-expected financial performance and a solid cash position provide resources to advance clinical programs and pursue strategic options without immediate dilution pressure.

Bears Say

Commercial And Partnership RiskSales projections were lowered to reflect partner requirements, signaling that commercial upside may be contingent on securing favorable partnership terms and could be constrained if agreements are unfavorable.

Comparative Efficacy In PACC MutationsObserved activity in PACC mutations appears weaker than a key competitor in patients without CNS involvement, which may reduce the drug's competitiveness in that subgroup.

Safety And TolerabilityA high frequency of adverse events resulted in dose reductions for a majority of patients, which could limit the ability to maintain optimal dosing and complicate clinical development.

Black Diamond Therapeutics News

Black Diamond Therapeutics price target lowered to $8 from $9 at Piper Sandler

Piper Sandler analyst Kelsey Goodwin lowered the firm’s price target on Black Diamond Therapeutics (BDTX) to $8 from...

15h ago

BDTX

3 Low P/E Ratio Stocks Poised to Surge Over 100% in 2026

Using the TipRanks Stock Screener Tool, we identified three companies that have low Price-to-Earnings (P/E) ratios and hold a “Strong Buy”...

25d ago

BDTX

BTBT

Black Diamond Advances Silevertinib Combo Into Phase 2 for Hard‑to‑Treat Brain Cancer

Black Diamond Therapeutics, Inc. ($BDTX) announced an update on their ongoing clinical study. Study Overview Black Diamond Therapeutics...

8d ago

BDTX

Promising Phase 2 Trial Results and Strategic Partnerships Support Buy Rating for Black Diamond Therapeutics

Stifel Nicolaus analyst Laura Prendergast has maintained their bullish stance on BDTX stock, giving a Buy rating yesterday....

1M ago

BDTX

Black Diamond Therapeutics downgraded to Neutral from Buy at Guggenheim

Guggenheim analyst Brad Canino downgraded Black Diamond Therapeutics (BDTX) to Neutral from Buy without a price target While...

1M ago

BDTX

Black Diamond Therapeutics downgraded to Neutral from Buy at Guggenheim

Guggenheim analyst Brad Canino downgraded Black Diamond Therapeutics (BDTX) to Neutral from Buy. Published first on TheFly –...

1M ago

BDTX

Promising Potential of Silevertinib in EGFR-Mutant NSCLC: Buy Rating Reiterated

Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on Black Diamond Therapeutics and keeping the price...

1M ago

BDTX

Black Diamond Reports Promising Phase 2 Lung Cancer Data

The latest announcement is out from Black Diamond Therapeutics ( ($BDTX) ). On December 3, 2025, Black Diamond...

1M ago

BDTX

Black Diamond Therapeutics announces data from Phase 2 trial of silevertinib

Black Diamond Therapeutics (BDTX) announced topline data from its Phase 2 trial of silevertinib in frontline non-small cell...

1M ago

BDTX

Black Diamond Therapeutics assumed with an Overweight at Piper Sandler

Piper Sandler assumed coverage of Black Diamond Therapeutics (BDTX) with an Overweight rating and $9 price target Black...

2M ago

BDTX

Black Diamond Therapeutics files $500M mixed securities shelf

17:22 EST Black Diamond Therapeutics (BDTX) files $500M mixed securities shelf Published first on TheFly – the ultimate...

2M ago

BDTX

Promising Clinical Developments and Strong Financials Justify Buy Rating for Black Diamond Therapeutics

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Black Diamond Therapeutics today and set a price...

2M ago

BDTX

Black Diamond Therapeutics Reports Positive Financial Turnaround

Black Diamond Therapeutics, Inc. ( ($BDTX) ) has released its Q3 earnings. Here is a breakdown of the...

2M ago

BDTX

Black Diamond Therapeutics reports Q3 EPS (15c), consensus (23c)

“We are looking forward to sharing a clinical update later this quarter from our silevertinib Phase 2 trial...

2M ago

BDTX

BDTX FAQ

What was Black Diamond Therapeutics, Inc.’s price range in the past 12 months?

Black Diamond Therapeutics, Inc. lowest stock price was $1.20 and its highest was $4.94 in the past 12 months.

What is Black Diamond Therapeutics, Inc.’s market cap?

Black Diamond Therapeutics, Inc.’s market cap is $158.96M.

When is Black Diamond Therapeutics, Inc.’s upcoming earnings report date?

Black Diamond Therapeutics, Inc.’s upcoming earnings report date is Mar 18, 2026 which is in 60 days.

How were Black Diamond Therapeutics, Inc.’s earnings last quarter?

Black Diamond Therapeutics, Inc. released its earnings results on Nov 06, 2025. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.234 by $0.084.

Is Black Diamond Therapeutics, Inc. overvalued?

According to Wall Street analysts Black Diamond Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Black Diamond Therapeutics, Inc. pay dividends?

Black Diamond Therapeutics, Inc. does not currently pay dividends.

What is Black Diamond Therapeutics, Inc.’s EPS estimate?

Black Diamond Therapeutics, Inc.’s EPS estimate is -0.18.

How many shares outstanding does Black Diamond Therapeutics, Inc. have?

Black Diamond Therapeutics, Inc. has 56,974,915 shares outstanding.

What happened to Black Diamond Therapeutics, Inc.’s price movement after its last earnings report?

Black Diamond Therapeutics, Inc. reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.234. Following the earnings report the stock price went up 2.842%.

Which hedge fund is a major shareholder of Black Diamond Therapeutics, Inc.?

Currently, no hedge funds are holding shares in BDTX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Black Diamond Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

19.23%

Trailing 12-Months

Asset Growth

14.39%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Black Diamond Therapeutics (BDTX) Earnings & Revenues

Historic Earnings Reports

BDTX Stock 12 Month Forecast

Average Price Target

$9.00

▲(222.58% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","2.75":"$2.75","5.5":"$5.5","8.25":"$8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.43,3.0123076923076924,3.594615384615385,4.176923076923077,4.759230769230769,5.341538461538462,5.923846153846155,6.506153846153847,7.088461538461539,7.670769230769231,8.253076923076923,8.835384615384616,9.417692307692308,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.43,2.9353846153846157,3.440769230769231,3.9461538461538463,4.451538461538462,4.956923076923077,5.462307692307693,5.9676923076923085,6.473076923076924,6.97846153846154,7.483846153846155,7.989230769230771,8.494615384615384,{"y":9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.43,2.8584615384615386,3.286923076923077,3.7153846153846155,4.143846153846154,4.572307692307692,5.000769230769231,5.42923076923077,5.857692307692308,6.286153846153846,6.714615384615385,7.143076923076924,7.571538461538463,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.14,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.62,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.01,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.49,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.7,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.37,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.48,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.59,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.72,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.87,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.77,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.43,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >